Curcumin supplementation for patients with locally advanced cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the effects of curcumin supplementation on patients with locally advanced cervical cancer. Participants will receive different doses of curcumin, with or without piperine, during their chemoradiotherapy treatment. The study will assess the impact of curcumin on p53 levels and apoptosis in tumor cells, as well as the safety of various dosages. By comparing six groups, researchers hope to identify the most effective and safe dose of curcumin for enhancing treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Understanding the nature of the study and giving a written consent report.
2. Women \> 18 years old.
3. ECOG performance status: 0-2.
4. Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
5. Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.
6. Classified with clinical stage IB3-IVA (FIGO 2018).
7. Candidates to receive concomitant QT-RT followed by BT.
8. With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria.
9. Patients without prior treatment based on QT-RT.
10. Hemoglobin ≥ 10 g/dL.
11. Leukocytes ≥ 4000/mm3.
12. Platelets ≥ 100,000/mm3.
13. Adequate liver function.

Exclusion Criteria:

1. Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.
2. Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.
3. Patients receiving concomitant treatment with an experimental drug.
4. Patients with vesicovaginal or vesicorectal fistula are diagnosed.
5. Patients with previous or concomitant malignancy except non-melanoma skin carcinoma.

Where it's running

• Instituto Nacional de Cancerología
  Mexico City, Mexico City, Mexico Recruiting

Study contacts

• Principal investigator: Denisse Castro, RDN, PhD — Conacyt / National Cancer Institute of Mexico
• Study coordinator: Denisse Castro-Eguiluz, RDN, PhD
• Email: adcastro@conahcyt.mx
• Phone: +525541940650

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Vitamin D Status and Outcomes in Locally Advanced Cervical Cancer treated with chemoradiotherapy

  This study tests whether pretreatment vitamin D levels can predict how well women with locally advanced cervical cancer respond to standard chemoradiotherapy.

  Recruiting University of Kragujevac · Kragujevac, Šumadija · NCT07743918

• Patient-tailored 3D-printed ARCHITECT applicator for cervical cancer brachytherapy

  We’re testing a 3D-printed, one-time use ARCHITECT applicator to see if it safely helps deliver brachytherapy for locally advanced cervical cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07435987

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Cadonilimab plus cisplatin given before surgery for locally advanced cervical cancer

  This study will test whether giving cadonilimab together with cisplatin before surgery helps people with resectable, locally advanced cervical cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07104149

• Pre-surgery iparomlimab and tuvonralimab with chemotherapy for locally advanced cervical cancer

  This phase 2 trial tests whether giving iparomlimab and tuvonralimab with chemotherapy before surgery helps people with locally advanced cervical cancer shrink their tumors and improve outcomes.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07055399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.